# Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

> **NCT00073580** · PHASE3 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 88 (actual)

## Conditions studied

- Thrombocytopenia
- Thrombosis
- Cardiac Disease
- Coronary Artery Bypass Surgery

## Interventions

- **DRUG:** Angiomax (bivalirudin) anticoagulant

## Key facts

- **NCT ID:** NCT00073580
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2005-09
- **Final completion:** —
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2018-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073580, "Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00073580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*